Bladder cancer is the 10th most common cancer in the world. In recent years, several new agents have been approved or are in development for the treatment of urothelial tumors. In this webinar, we will review the evolving therapeutic landscape of localized and advanced urothelial carcinoma (UC). We will describe how to improve personalized and targeted therapeutic strategies through the administration of highly selective and well-tolerated drugs in both neoadjuvant and adjuvant settings. In addition, we will focus on any technological advances in urinary marker and surgery that can improve risk stratification and outcomes for bladder cancer patients.
